Temsirolimus with or without megestrol acetate and tamoxifen for endometrial cancer: a gynecologic oncology group study.
about
Chemoresistance and targeted therapies in ovarian and endometrial cancersEndometrial Carcinoma: Role of Current and Emerging Biomarkers in Resolving Persistent Clinical DilemmasPhase I study of oral ridaforolimus in combination with paclitaxel and carboplatin in patients with solid tumor cancers.Fulvestrant for the treatment of endometrial cancer.Phase II study of everolimus and letrozole in patients with recurrent endometrial carcinoma.Influence of AKT on progesterone action in endometrial diseases.A phase II evaluation of selumetinib (AZD6244, ARRY-142886), a selective MEK-1/2 inhibitor in the treatment of recurrent or persistent endometrial cancer: an NRG Oncology/Gynecologic Oncology Group studyDownregulation of FOXO1 mRNA levels predicts treatment failure in patients with endometrial pathology conservatively managed with progestin-containing intrauterine devicesTumor mutational analysis of GOG248, a phase II study of temsirolimus or temsirolimus and alternating megestrol acetate and tamoxifen for advanced endometrial cancer (EC): An NRG Oncology/Gynecologic Oncology Group studyA Review of mTOR Pathway Inhibitors in Gynecologic CancerAssociation of Hormone Receptor Expression with Survival in Ovarian Endometrioid Carcinoma: Biological Validation and Clinical Implications.Exploiting the therapeutic potential of the PI3K-AKT-mTOR pathway in enriched populations of gynecologic malignancies.Emerging drugs for endometrial cancer.Endometrial cancer: redefining the molecular-targeted approach.Targeting angiogenesis in endometrial cancer - new agents for tailored treatments.An update on the current pharmacotherapy for endometrial cancer.New Targeted Agents in Endometrial Cancer: Are We Really Making Progress?High stathmin expression is a marker for poor clinical outcome in endometrial cancer: An NRG oncology group/gynecologic oncology group study.Chemotherapy for Endometrial Cancer in Adjuvant and Advanced Disease SettingsMoving forward with actionable therapeutic targets and opportunities in endometrial cancer: NCI clinical trials planning meeting report on identifying key genes and molecular pathways for targeted endometrial cancer trials.Treatment-related fatigue with everolimus and temsirolimus in patients with cancer-a meta-analysis of clinical trials.New therapies for advanced, recurrent, and metastatic endometrial cancers.Norethindrone substituted for megestrol in the treatment of metastatic endometrial carcinoma: Three cases.Clinical trials in gynecologic oncology: Past, present, and future.Phase II study of the PI3K inhibitor BKM120 in patients with advanced or recurrent endometrial carcinoma: a stratified type I-type II study from the GINECO group.
P2860
Q28073246-2EFA5E15-3AA0-4198-8AB5-C2985816E4E5Q28074769-F92B229D-B65C-46EB-9E5B-18A429AF8986Q33442539-AE6E3C65-3DB0-4ACF-91FF-E5164B1416ECQ34514391-30F725A0-E797-4400-9D65-4C270C2BE205Q35144264-D8AF10EC-2B97-4405-9300-754E806B390DQ35617565-D5B6444A-CB74-4CB3-801D-49E7CF896FD0Q35748507-096343FE-950A-4FDB-BB8A-74788C39EC12Q36669005-E033159A-2908-4F03-A429-1250279CABA4Q37429034-DD4B5BD7-22DF-4AAC-A7AC-F80DB1F1D3C0Q37668889-2AACCAE6-E584-48D4-A371-6903594C2917Q37729055-538E8367-0483-47CD-AA41-1012082D839EQ38258712-31DC8B3D-CDD7-4F16-AAB3-D71AB1E480D6Q38261469-ABC34C55-2052-43A0-BCF4-CAF1263E8226Q38454955-3967605A-1690-4853-8976-A57A3681E5D6Q38631272-B86512C4-34E2-4EC7-A72C-4B16676797EDQ38656675-09F84063-488D-44AA-AB07-6544B2CA72A5Q38753038-171C9238-BB60-4D29-99E8-2767E25238E3Q38770214-739DA921-BBAC-40F6-A4E3-655AA57448BDQ38895754-66DDD587-C316-45DD-9B2A-67E91D1B0313Q45848384-C0D312A5-9CE7-4216-BDAD-2A56C2ACF3A1Q46909057-1C9E47A0-3DE5-40BD-AB67-D56C7A97EFB9Q47103210-8A80ABD4-ADB0-4C0B-A77D-21FC4810D3ABQ47163058-30A5E0F4-F342-4B90-80BA-1FE8C2D7495BQ47796770-70576B47-A2CF-4D69-88A7-AA47DBB33E95Q55005815-1DC4F013-78EB-47CC-86A1-D395A0EB7C86
P2860
Temsirolimus with or without megestrol acetate and tamoxifen for endometrial cancer: a gynecologic oncology group study.
description
2014 nî lūn-bûn
@nan
2014 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Temsirolimus with or without m ...... ecologic oncology group study.
@ast
Temsirolimus with or without m ...... ecologic oncology group study.
@en
type
label
Temsirolimus with or without m ...... ecologic oncology group study.
@ast
Temsirolimus with or without m ...... ecologic oncology group study.
@en
prefLabel
Temsirolimus with or without m ...... ecologic oncology group study.
@ast
Temsirolimus with or without m ...... ecologic oncology group study.
@en
P2093
P2860
P1433
P1476
Temsirolimus with or without m ...... ecologic oncology group study.
@en
P2093
Brandon Marzullo
Gini F Fleming
Gordon Downey
Henry D Reyes
James J Burke
Joan L Walker
Linda Van Le
Michael Pearl
Parviz Hanjani
Richard J Zaino
P2860
P304
P356
10.1016/J.YGYNO.2014.01.015
P407
P577
2014-01-20T00:00:00Z